搜尋
Redhill Biopharma Ltd
RDHL添加自選
0.812USD
-0.026-3.11%
收盤 07/02, 13:00（美東）報價延遲15分鐘
4.14M總市值
虧損本益比TTM
關鍵數據
0.880今開
0.890最高
41.70K成交量
虧損本益比TTM
--本益比動
--股利TTM
0.82%換手率
0.830昨收
0.810最低
6.92K成交額
虧損本益比靜
0.97市淨率
0.00%股息率 TTM
-37.25%ROA
3.31052週最高
1.12量比
-8.27M淨利潤
5.09M總股本
-0.1000每股盈餘TTM
4.99Beta
-1708.61%ROE
0.71052週最低
9.63%振幅
100.00%毛利率
4.14M總市值
-3.04回報/風險
5.60%風險率
TradingKey Redhill Biopharma Ltd股票評分
單位: USD 更新時間: 2026-07-02操作建議
Redhill Biopharma Ltd當前公司基本面數據相對非常健康，增長潛力很大。當前估值低估，在藥品行業排名134/157位。機構持股佔比非常高，中期看，股價處於平穩狀態。近一個月，市場表現非常差，基本面和技術面綜合得分也較低。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Redhill Biopharma Ltd評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Redhill Biopharma Ltd亮點
亮點風險
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
業績增長期
公司處於發展階段，最新年度總收入286.00K美元
估值低估
公司最新PE估值-8.12，處於3年歷史低位
機構加倉
最新機構持股504.44K股，環比增加40.77%
分析師目標
基於
0
分析師
--
評級
--
目標均價
--
漲幅空間
Redhill Biopharma Ltd新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Redhill Biopharma Ltd簡介
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
公司代碼RDHL
公司Redhill Biopharma Ltd
CEOBen-Asher (Dror)
網址https://www.redhillbio.com/
相關品種
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
常見問題
Redhill Biopharma Ltd(RDHL)的當前股價是多少？
Redhill Biopharma Ltd(RDHL)的當前股價是 0.81。
Redhill Biopharma Ltd 的股票代碼是什麼？
Redhill Biopharma Ltd的股票代碼是RDHL。
Redhill Biopharma Ltd股票的52週最高點是多少？
Redhill Biopharma Ltd股票的52週最高點是3.31。
Redhill Biopharma Ltd股票的52週最低點是多少？
Redhill Biopharma Ltd股票的52週最低點是0.71。
Redhill Biopharma Ltd的市值是多少？
Redhill Biopharma Ltd的市值是4.14M。
Redhill Biopharma Ltd(RDHL)股票的每股收益（EPS TTM）是多少
Redhill Biopharma Ltd(RDHL)股票的每股收益（EPS TTM）是-0.10。